Prudential Financial Inc. Has $6.02 Million Position in CareDx, Inc (NASDAQ:CDNA)

Prudential Financial Inc. boosted its position in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 58.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 281,339 shares of the company's stock after buying an additional 103,862 shares during the period. Prudential Financial Inc. owned 0.52% of CareDx worth $6,023,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Intech Investment Management LLC acquired a new stake in CareDx in the 3rd quarter valued at about $449,000. Charles Schwab Investment Management Inc. raised its position in CareDx by 2.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 499,480 shares of the company's stock valued at $15,596,000 after purchasing an additional 13,547 shares during the period. FMR LLC grew its holdings in shares of CareDx by 802.4% during the 3rd quarter. FMR LLC now owns 625,550 shares of the company's stock worth $19,533,000 after purchasing an additional 556,230 shares during the period. BNP Paribas Financial Markets increased its position in shares of CareDx by 1,784.8% during the third quarter. BNP Paribas Financial Markets now owns 49,420 shares of the company's stock valued at $1,543,000 after acquiring an additional 46,798 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of CareDx by 376.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,631 shares of the company's stock worth $363,000 after purchasing an additional 9,192 shares during the period.

Remove Ads

Wall Street Analyst Weigh In

CDNA has been the subject of several research reports. StockNews.com raised CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. HC Wainwright dropped their price target on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Stephens restated an "overweight" rating and set a $40.00 price objective on shares of CareDx in a research report on Thursday, February 27th. Finally, Wells Fargo & Company raised CareDx from an "underweight" rating to an "equal weight" rating and dropped their price objective for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, CareDx has a consensus rating of "Moderate Buy" and an average target price of $31.83.

CareDx Stock Performance

CareDx stock traded down $0.09 during trading on Friday, reaching $17.28. 1,029,539 shares of the company's stock were exchanged, compared to its average volume of 848,976. CareDx, Inc has a 52-week low of $7.42 and a 52-week high of $34.84. The company's 50-day moving average is $20.90 and its two-hundred day moving average is $23.28. The firm has a market cap of $957.76 million, a price-to-earnings ratio of -6.40 and a beta of 2.17.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. Analysts anticipate that CareDx, Inc will post -0.9 EPS for the current year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.